These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16621242)

  • 61. The effects of bone therapy on tibial bone loss in young women with anorexia nervosa.
    Nakahara T; Nagai N; Tanaka M; Muranaga T; Kojima S; Nozoe S; Naruo T
    Int J Eat Disord; 2006 Jan; 39(1):20-6. PubMed ID: 16231362
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
    Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
    Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM; Valeriano J; Vasey FB; Carter JD
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Corticosteroid-induced osteoporosis: guidelines for prevention--are they useful?
    Reid DM
    Br J Rheumatol; 1997 Oct; 36(10):1035-7. PubMed ID: 9374917
    [No Abstract]   [Full Text] [Related]  

  • 65. [Osteodeficiency in chronic pancreatitis: ways of correction].
    Babinets' LS; Semenova IV; Borovyk IO
    Lik Sprava; 2014 Nov; (11):134-8. PubMed ID: 25528852
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The role of risedronate in osteopenia in Crohn's disease.
    Buchan A; Manuel A
    Gut; 2015 Jan; 64(1):185. PubMed ID: 24304669
    [No Abstract]   [Full Text] [Related]  

  • 67. Authors' response: The role of risedronate in osteopenia in Crohn's disease.
    van Bodegraven AA; Witte BI; Lips P;
    Gut; 2015 Jan; 64(1):185-6. PubMed ID: 24569060
    [No Abstract]   [Full Text] [Related]  

  • 68. Calcium and vitamin D therapy in corticosteroid-induced bone loss: what is the evidence?
    Adachi JD; Ioannidis G
    Calcif Tissue Int; 1999 Oct; 65(4):332-6. PubMed ID: 10485987
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Evidence-based therapy of osteoporosis--comment on DMW 17/2003].
    Traut V
    Dtsch Med Wochenschr; 2003 Jul; 128(30):1618; author reply 1618. PubMed ID: 12884153
    [No Abstract]   [Full Text] [Related]  

  • 70. [Severe oesophagus injury as a complication during treatment with risedronic acid].
    Bijlsma A; Blokzijl H; Vecht J
    Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2105-7. PubMed ID: 18856023
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bone health.
    Morrow A
    Nurs Stand; 2014 Jan 29-Feb 4; 28(22):61. PubMed ID: 24471639
    [No Abstract]   [Full Text] [Related]  

  • 72. Current practices for the prophylaxis against bone mineral density loss in patients with autoimmune blistering disease treated with corticosteroids: an expert survey.
    Amber KT; Grando SA
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):e416-e418. PubMed ID: 29705983
    [No Abstract]   [Full Text] [Related]  

  • 73. Risedronate for the prevention of hip fractures: concern about validity of trials.
    Halbekath JM; Schenk S; von Maxen A; Meyer G; Mühlhauser I
    Arch Intern Med; 2007 Mar; 167(5):513-4; author reply 514-5. PubMed ID: 17353501
    [No Abstract]   [Full Text] [Related]  

  • 74. Importance of negative trials.
    Dar Santos AE
    Inflamm Bowel Dis; 2007 Dec; 13(12):1587-8. PubMed ID: 17663427
    [No Abstract]   [Full Text] [Related]  

  • 75. Prevention of Glucocorticoid-Induced Osteoporosis: Clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting.
    Carter M
    J Clin Densitom; 2019; 22(1):25-30. PubMed ID: 29729949
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases.
    Cowan S; Morin S; Ernst P
    Thorax; 1998 May; 53(5):331-2. PubMed ID: 9708219
    [No Abstract]   [Full Text] [Related]  

  • 77. How to prevent glucocorticoid-induced osteoporosis.
    Bachmeyer C; Gauthier M
    Cleve Clin J Med; 2010 Nov; 77(11):762; author reply 762. PubMed ID: 21086710
    [No Abstract]   [Full Text] [Related]  

  • 78. Prevention and treatment of osteoporosis.
    Prestwood KM; Raisz LG
    Clin Cornerstone; 2002; 4(6):31-41. PubMed ID: 12739329
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prevention of osteoporosis in glucocorticoid-treated neurology patients.
    Lozsadi DA; Peters G; Sadik HY; Kellett MW; Fox SH; Smith DF
    Clin Neurol Neurosurg; 2006 Feb; 108(2):157-62. PubMed ID: 16303241
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A bright future for osteoporosis treatment.
    Jack D
    Drug News Perspect; 2005 Jun; 18(5):341-4. PubMed ID: 16193107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.